Search Results
Aug 28, 2026, 10:34 ET SF Intra-city's Strategic Leadership Drives Performance to New Heights in 1H 2026
its full–scenario, multi–category service capabilities enabling it to maintain good cooperative relationships with a multi–layered customer base; and (iii) further enhancement of economies of scale, optimisation of resource input strategies, refined rider network operations and the application of AI technologies
More news about: SF Intra-city
Aug 28, 2026, 10:10 ET BLACK PEARL EXTENDS TENDER OFFER FOR ALL OUTSTANDING SHARES OF SELECTIS HEALTH, INC.
satisfaction of the conditions to closing the transaction in the anticipated timeframe or at all; (ii) the failure to obtain necessary regulatory approvals; (iii) the ability to realize the anticipated benefits of the transaction; (iv) the ability to successfully integrate the businesses; (v) disruption from the
More news about: Black Pearl Equities
Aug 28, 2026, 09:59 ET YFORE, Pionier im Bereich digitaler Spiegel, stellt in Nordamerika sein komplettes Sortiment an intelligenten Spiegeln vor
Meilensteins stellte YFORE sein komplettes Sortiment an digitalen Spiegeln in ganz Nordamerika vor, das digitale Innenspiegel (CMS-I), digitale Außenspiegel (CMS-III) und automatisch abblendbare Spiegel umfasst, angeführt von der weltweiten Premiere seines Multifunktionsspiegels.
More news about: YFORE
Aug 28, 2026, 07:30 ET Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
Company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or the five-year anniversary of issuance, and (iii) accompanying Series B Warrants to purchase up to 2,064,000 ADSs (or pre-funded warrants in lieu thereof), which are exercisable immediately at a purchase
More news about: Kazia Therapeutics Limited
Aug 28, 2026, 07:00 ET InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation
pivotal trial of this combination regimen to further establish its clinical benefit. The company has submitted an IND application in China, for a phase III trial evaluating the efficacy and safety of ifebemtinib plus garsorasib versus investigators' choice of standard therapy for treatment of previously
More news about: InxMed Co., Ltd
Aug 28, 2026, 06:47 ET Digital Mirror Pioneer YFORE Unveils Full Intelligent Mirror Lineup in North America
the milestone, YFORE debuted its full digital mirror lineup across North America, spanning Interior Digital Mirrors (CMS-I), Exterior Side Mirrors (CMS-III), and Auto-Dimming Mirrors, led by the global debut of its Multifunctional Mirror.
More news about: YFORE
Aug 28, 2026, 06:23 ET Digital Mirror Pioneer YFORE Unveils Full Intelligent Mirror Lineup in North America
the milestone, YFORE debuted its full digital mirror lineup across North America, spanning Interior Digital Mirrors (CMS-I), Exterior Side Mirrors (CMS-III), and Auto-Dimming Mirrors, led by the global debut of its Multifunctional Mirror.
More news about: YFORE
Aug 28, 2026, 06:10 ET SEPTEMBER 21, 2026 INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Cogent Communications Holdings, Inc. and Announces that Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - CCOI
wavelength in a timely manner; (iii) that, as a result of (i)-(ii) above, defendants had materially misrepresented customer demand for Cogent's optical wavelength services and the nature of Cogent's purported "backlog" of wavelength orders; (iv) that, as a result of (i)-(iii) above, Cogent was not on track
More news about: Robbins Geller Rudman & Dowd LLP
Aug 28, 2026, 04:34 ET MINISO Group Announces 2026 June Quarter and Interim Unaudited Financial Results
(the "Equity Linked Securities"), and (iii) increased interest expenses mainly attributable to a borrowing in connection with the acquisition of the equity interest in Yonghui Superstores Co., Ltd * (永輝超市股份有限公司) ("Yonghui"). Both (ii) and (iii) are excluded in non-IFRS financial measures(2)
More news about: MINISO Group Holding Limited
Aug 27, 2026, 22:44 ET Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
chemotherapy in a randomized, double-blind Phase III trial. Ivonescimab combination therapy marks a significant advance in first-line sq-NSCLC treatment.EGFR-TKI-resistant NSCLC: In July 2026, an updated analysis of the global multicenter Phase III HARMONi study demonstrated continued OS improvement
More news about: Akeso, Inc.
Aug 27, 2026, 18:58 ET Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. The company has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.Samsung Biologics
More news about: Samsung Biologics
Aug 27, 2026, 18:20 ET Ecopetrol Announces the Second Convening of Bondholders' Meetings for Domestic Public Debt Bonds
Bondholders' Representatives for the appointment of the Chairperson and Secretary of the meeting, in accordance with Section 4.3.3 of Chapter I, Title I, Part III of Legal Circular 006 of 2025 issued by the Superintendencia Financiera de Colombia (Colombian Financial Superintendence).Appointment of the
More news about: Ecopetrol S.A.
Aug 27, 2026, 16:15 ET SEPTEMBER 21, 2026 PRIM INVESTOR DEADLINE: Primoris Services Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
risks of significant fixed-price renewable energy projects that were experiencing material cost overruns, execution problems, and schedule delays; and (iii) accordingly, defendants' statements regarding Primoris' estimating processes, project execution, ability to manage project risk, financial performance,
More news about: Robbins Geller Rudman & Dowd LLP
Aug 27, 2026, 16:15 ET Gap Inc. Reports Second Quarter Fiscal 2026 Results
and certain adjusted statement of operations metrics, including: (i) adjusted cost of goods sold and occupancy expenses; (ii) adjusted gross profit; (iii) adjusted gross margin; (iv) adjusted operating income; (v) adjusted operating margin; (vi) adjusted interest, net; (vii) adjusted income tax expense;
More news about: Gap Inc.
Aug 27, 2026, 16:09 ET Kazia Therapeutics Limited Announces Proposed Public Offering
Company's Stage IV triple-negative breast cancer (TNBC) data readout, expected in the second half of 2027, or the five-year anniversary of issuance, and (iii) accompanying Series B Warrants to purchase ADSs (or pre-funded warrants in lieu thereof), which are exercisable immediately at an exercise price equal
More news about: Kazia Therapeutics Limited
Aug 27, 2026, 16:04 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Datavault AI Inc. and Certain Officers - DVLT
for a $40,000 fine and a three-year ban from participating in a penny stock offering. Nor did the Company's announcement disclose that Edward Withrow III ("Withrow"), an individual listed as inventor alongside Defendant Bradley on multiple Data Vault Holdings patents, had a previous felony
More news about: Pomerantz LLP
Aug 27, 2026, 16:04 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Intuit Inc. and Certain Officers - INTU
marketing products and services in the United States. The Company has four reportable business segments: (i) Global Business Solutions; (ii) Consumer; (iii) Credit Karma; and (iv) ProTax. Intuit's Consumer segment provides do-it-yourself ("DIY") and assisted income tax preparation products and services
More news about: Pomerantz LLP
Aug 27, 2026, 16:04 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
joining the class action]On April 29, 2026, during during Regeneron's first quarter earnings call, the Company disclosed that the Phase III Fianlimab-Libtayo Study had been altered, expanding the number of patients in the study eligible for "analysis of progression-free survival."On
More news about: Pomerantz LLP
Aug 27, 2026, 16:04 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers - GUTS
therapy. The REMAIN-1 study is designed to include three distinct patient cohorts: (i) the REVEAL-1 Cohort; (ii) the REMAIN-1 Midpoint Cohort; and (iii) the REMAIN-1 Pivotal Cohort.At all relevant times, Defendants touted Revita's efficacy as observed in interim data readouts from the REVEAL-1
More news about: Pomerantz LLP
Aug 27, 2026, 16:04 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain Officers - PODD
heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.The truth began to emerge on March 12,
More news about: Pomerantz LLP
Aug 27, 2026, 16:04 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Insulet Corporation and Certain Officers - PODD
heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.The truth began to emerge on March 12,
More news about: Pomerantz LLP
Aug 27, 2026, 16:04 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Microvast Holdings, Inc. and Certain Officers - MVST
ability to reach its margin targets; (ii) Defendants overstated Microvast's ability to complete the Huzhou Phase 3.2 expansion by the end of 2025; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.The market received its first inkling of
More news about: Pomerantz LLP
Aug 27, 2026, 16:04 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD
safe than Defendants had led investors to believe; (ii) accordingly, ARD-101's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.The truth began to emerge on February 27,
More news about: Pomerantz LLP
Aug 27, 2026, 16:04 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Wix.com Ltd. and Certain Officers - WIX
relative to those offered by other companies; (ii) Wix had understated the costs associated with developing and promoting its AI product offerings; (iii) accordingly, Defendants overstated the commercial and financial benefits of Wix's AI product offerings; and (iv) as a result, Defendants' public statements
More news about: Pomerantz LLP
Aug 27, 2026, 16:01 ET Workday Announces Fiscal 2027 Second Quarter Financial Results
infrastructure operations; (ii) service outages, delays in the deployment of our applications, and the failure of our applications to perform properly; (iii) competitive factors, including pricing pressures, industry consolidation, entry of new competitors and new applications, advancements in technology,
More news about: Workday, Inc.